NURS 5433 PACKAGE DEAL REVIEW TEST
PAPER 2026 FULL SOLUTIONS GRADED A+
⩥ Low ICS.
Answer: *Budesonide: 180-360 mcg/day (Pulmicort) and Fluticasone
propionate: 100-250 mcg/day (Flovent)
Beclomethasone: 80-160 mcg/day
Mometasone: 110 mcg/day
⩥ Medium ICS.
Answer: • Budesonide: 361-720 mcg/day (Pulmicort )
• Fluticasone propionate: 251-500 mcg/day (Flovent )
• Beclomethasone: 161-320 mcg/day
• Mometasone: 220-440 mcg/day
⩥ High ICS.
Answer: • Budesonide: >720 mcg/day (Pulmicort)
• Fluticasone propionate: >500 mcg/day (Flovent HFA)
• Beclomethasone: >320 mcg/day
• Mometasone: >440 mcg/day
,⩥ SABA.
Answer: Short-acting beta agonists such as salbutamol (albuterol) and
terbutaline.
⩥ LAMA.
Answer: Long-acting muscarinic antagonists like tiotropium and
beclomethasone-formoterol glycopyrronium.
⩥ LABA.
Answer: Long-acting beta agonists such as salmeterol and formoterol.
⩥ ICS and LABA combo.
Answer: Combination medications like beclomethasone/formoterol and
budesonide/formoterol.
⩥ SAMA.
Answer: Short-acting muscarinic antagonists such as ipratropium
bromide and oxitropium bromide (combo with SABA).
⩥ Oral corticosteroids.
Answer: Prednisone, prednisolone, and methylprednisolone.
⩥ Anti-IgE.
, Answer: Omalizumab, a medication used for asthma management.
⩥ Leukotriene modifiers (LTRA).
Answer: Medications such as montelukast, pranlukast, and zileuton.
⩥ Sustained step-up treatment.
Answer: Increase treatment for at least 2-3 months if symptoms persist
despite controller treatment.
⩥ Common issues to consider before stepping up asthma tx.
Answer: Incorrect inhaler technique, poor adherence, modifiable risk
(smoking)
⩥ Short-term step-up treatment.
Answer: Temporary increase in treatment for 1-2 weeks during
exacerbations.
⩥ Day-to-day adjustment.
Answer: Using as-needed low dose ICS-formoterol for mild asthma or
ICS-formoteral as a maintenance and reliever therapy.
⩥ Stepping down treatment.
PAPER 2026 FULL SOLUTIONS GRADED A+
⩥ Low ICS.
Answer: *Budesonide: 180-360 mcg/day (Pulmicort) and Fluticasone
propionate: 100-250 mcg/day (Flovent)
Beclomethasone: 80-160 mcg/day
Mometasone: 110 mcg/day
⩥ Medium ICS.
Answer: • Budesonide: 361-720 mcg/day (Pulmicort )
• Fluticasone propionate: 251-500 mcg/day (Flovent )
• Beclomethasone: 161-320 mcg/day
• Mometasone: 220-440 mcg/day
⩥ High ICS.
Answer: • Budesonide: >720 mcg/day (Pulmicort)
• Fluticasone propionate: >500 mcg/day (Flovent HFA)
• Beclomethasone: >320 mcg/day
• Mometasone: >440 mcg/day
,⩥ SABA.
Answer: Short-acting beta agonists such as salbutamol (albuterol) and
terbutaline.
⩥ LAMA.
Answer: Long-acting muscarinic antagonists like tiotropium and
beclomethasone-formoterol glycopyrronium.
⩥ LABA.
Answer: Long-acting beta agonists such as salmeterol and formoterol.
⩥ ICS and LABA combo.
Answer: Combination medications like beclomethasone/formoterol and
budesonide/formoterol.
⩥ SAMA.
Answer: Short-acting muscarinic antagonists such as ipratropium
bromide and oxitropium bromide (combo with SABA).
⩥ Oral corticosteroids.
Answer: Prednisone, prednisolone, and methylprednisolone.
⩥ Anti-IgE.
, Answer: Omalizumab, a medication used for asthma management.
⩥ Leukotriene modifiers (LTRA).
Answer: Medications such as montelukast, pranlukast, and zileuton.
⩥ Sustained step-up treatment.
Answer: Increase treatment for at least 2-3 months if symptoms persist
despite controller treatment.
⩥ Common issues to consider before stepping up asthma tx.
Answer: Incorrect inhaler technique, poor adherence, modifiable risk
(smoking)
⩥ Short-term step-up treatment.
Answer: Temporary increase in treatment for 1-2 weeks during
exacerbations.
⩥ Day-to-day adjustment.
Answer: Using as-needed low dose ICS-formoterol for mild asthma or
ICS-formoteral as a maintenance and reliever therapy.
⩥ Stepping down treatment.
